ATE517347T1 - Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit - Google Patents

Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit

Info

Publication number
ATE517347T1
ATE517347T1 AT05853035T AT05853035T ATE517347T1 AT E517347 T1 ATE517347 T1 AT E517347T1 AT 05853035 T AT05853035 T AT 05853035T AT 05853035 T AT05853035 T AT 05853035T AT E517347 T1 ATE517347 T1 AT E517347T1
Authority
AT
Austria
Prior art keywords
arginine
diagnosis
decrease
conditions related
bioavailability
Prior art date
Application number
AT05853035T
Other languages
English (en)
Inventor
Claudia Morris
Stanley Hazen
Original Assignee
Childrens Hosp & Res Ct Oak
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hosp & Res Ct Oak, Cleveland Clinic Foundation filed Critical Childrens Hosp & Res Ct Oak
Application granted granted Critical
Publication of ATE517347T1 publication Critical patent/ATE517347T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806Determination of free amino acids
    • G01N33/6812Assays for specific amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/978Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases
    • G01N2800/122Chronic or obstructive airway disorders, e.g. asthma COPD
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/22Haematology
    • G01N2800/224Haemostasis or coagulation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664Blood serum or blood plasma standard or control
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • Y10T436/171538Urea or blood urea nitrogen
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/17Nitrogen containing
    • Y10T436/177692Oxides of nitrogen

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05853035T 2004-12-01 2005-12-01 Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit ATE517347T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63257204P 2004-12-01 2004-12-01
PCT/US2005/043998 WO2006060793A2 (en) 2004-12-01 2005-12-01 Diagnosis of conditions associated with decreased arginine bioavailability

Publications (1)

Publication Number Publication Date
ATE517347T1 true ATE517347T1 (de) 2011-08-15

Family

ID=36565851

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05853035T ATE517347T1 (de) 2004-12-01 2005-12-01 Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit

Country Status (5)

Country Link
US (2) US7648840B2 (de)
EP (1) EP1825261B1 (de)
AT (1) ATE517347T1 (de)
CA (1) CA2587647C (de)
WO (1) WO2006060793A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1596854A4 (de) 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
WO2006060793A2 (en) * 2004-12-01 2006-06-08 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
EP2409157B1 (de) * 2009-03-20 2015-11-04 The Cleveland Clinic Foundation Citrullin als risikoindikator für herz-kreislauf-erkrankung
WO2010147952A1 (en) * 2009-06-15 2010-12-23 The Cleveland Clinic Foundation Methylated arginine metabolites as risk predictors of cardiovascular disease
WO2012158518A1 (en) * 2011-05-13 2012-11-22 The Penn State Research Foundation Treatment of renal injury
WO2015179952A1 (en) * 2014-05-26 2015-12-03 Mcmaster University A metabolite panel for improved screening and diagnostic testing of cystic fibrosis
CN109154621B (zh) * 2016-05-17 2022-08-05 国立大学法人大阪大学 肾脏病的预后预测方法及系统
US11655210B2 (en) 2018-05-18 2023-05-23 The General Hospital Corporation Compound for improving L-arginine bioavailability
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096037A (en) * 1976-05-24 1978-06-20 Pitman-Moore, Inc. Arginase test
JPS6359899A (ja) * 1986-09-01 1988-03-15 Advance Co Ltd 癌診断方法及びキツト
EP0441119A3 (en) 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
WO1999043308A2 (en) 1998-02-27 1999-09-02 Marlene Rabinovitch Treating pulmonary hypertension through tenascin suppression and elastase inhibition
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
WO2002004465A1 (en) * 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
AU2001290879A1 (en) 2000-09-15 2002-03-26 California Institute Of Technology Microfabricated crossflow devices and methods
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
EP1596854A4 (de) * 2003-02-14 2007-06-06 Childrens Hosp & Res Ct Oak Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase
WO2006060793A2 (en) * 2004-12-01 2006-06-08 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability

Also Published As

Publication number Publication date
US20100196939A1 (en) 2010-08-05
EP1825261B1 (de) 2011-07-20
WO2006060793A2 (en) 2006-06-08
CA2587647A1 (en) 2006-06-08
US20060160236A1 (en) 2006-07-20
EP1825261A4 (de) 2009-01-07
CA2587647C (en) 2017-03-28
WO2006060793A3 (en) 2006-12-28
US7648840B2 (en) 2010-01-19
US8309320B2 (en) 2012-11-13
EP1825261A2 (de) 2007-08-29

Similar Documents

Publication Publication Date Title
EA201391627A1 (ru) Анализ на наличие лизилоксидазоподобных белков 2 и способы его применения
EP1953527A3 (de) Probenanalysegerät und Computerprogrammprodukt
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2008070865A3 (en) Materials and methods for efficient and accurate detection of analytes
WO2007002579A3 (en) Assay cartridges and methods for point of care instruments
DK2021794T3 (da) Anvendelse af protein S100A 12 som en markør for colorektal cancer
EP2319941A3 (de) Methode und vorrichtung zur korrelation von biomarker produktmengen mit krankheiten
MX2013003038A (es) Espectroscopia raman para operaciones de bioprocesos.
ATE549624T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von grippe
ATE517347T1 (de) Diagnose von leiden in zusammenhang mit verminderter arginin-bioverfügbarkeit
ATE532063T1 (de) Elektrochemischer biosensor
WO2007114986A3 (en) Cooperative probes and methods of using them
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
WO2007134028A3 (en) Biomarkers for depression and methods using the same
EP2081029A3 (de) Biomarker zur Diagnose diabetischer Retinopathie
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
EP2238431A4 (de) Entwicklung und verwendung von cysteinmarkierten fluoreszierenden sonden aus ungebundenen analyten
ATE443775T1 (de) Hif-prolylhydroxylase-aktivitätstest
WO2007084397A3 (en) Processing of slpi by chymase
NZ592819A (en) Thyroid analyte detection and measurement
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
TR201900481T4 (tr) Bağışıklık testi için aparat ve kit.
WO2007103211A3 (en) Methods to identify fat and lean animals using class predictors
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties